The matrix fibronectin protein is a multifunctional adhesive molecule that promotes migration and invasiveness of many tumors including melanomas. Increased fibronectin synthesis has been associated with the metastatic potential of melanoma cells; however, the molecular mechanisms underlying fibronectin overexpression during melanoma development are poorly understood. We report that hepatocyte growth factor/scatter factor (HGF) induces fibronectin expression and its extracellular assembly on the surface of melanoma cells through activation of mitogen-activated protein (MAP) kinase pathway, and induction and transcriptional activation of Early growth response-1 (Egr-1). Inhibition of B-RAF/ MAP kinase pathway by dominant-negative mutants and by U0126-abrogated HGF-induced Egr-1, and chromatin immunoprecipitation showed that Egr-1 is bound to the fibronectin promoter in response to HGF. Exogenously expressed Egr-1 increased fibronectin levels, while blockage of Egr-1 activation by expression of the Egr-1 corepressor NAB2 interfered with the upregulation of fibronectin synthesis induced by HGF, indicating that Egr-1 exerts a significant role in fibronectin expression in response to HGF. Finally, analysis of the expression pattern of fibronectin in melanoma cells demonstrated that fibronectin levels are correlated with constitutive MAP kinase signaling. Our data define a novel mechanism that might have important implications in regulation of melanoma progression by autocrine HGF signaling or by constitutive activation of MAP kinase pathway.
Introduction
Malignant transformation is associated with alterations in cell-extracellular matrix (ECM) interactions that lead to major changes in adhesion and migration processes, and aberrant adhesion-mediated signaling (Sage, 2001 ). Fibronectin, a major constituent of ECMs, plays an important role during embryogenesis, wound healing and cancer invasion by promoting cell adhesion, motility, cell cycle progression and cell survival (Hynes and Yamada, 1982; Humphries et al., 1989; Frisch and Ruoslahti, 1997) . Fibronectin serves as a ligand for integrin family of cell adhesion receptors (Giancotti and Ruoslahti, 1999) . It is generally accepted that modulating levels of fibronectin in the tumor environment may influence tumor cell behavior. Reduction or loss of fibronectin expression has been observed in many transformed cells in culture (Ruoslahti and Giancotti, 1989) . However, overexpression of fibronectin is associated with various human tumor cells including colorectal cancer, breast carcinoma, head and neck squamous carcinoma and metastatic melanoma (Zhang et al., 1997; Bittner et al., 2000; Al Moustafa et al., 2002; Jiang et al., 2002) .
Cutaneous melanoma is a malignant tumor deriving from the transformation of pigments producing melanocytes (Goding, 2000) . Its incidence is increasing at a dramatic rate. Melanoma has a high capability of invasion and rapid metastasis to other organs (Goding, 2000) . Increased fibronectin production has been correlated with the acquisition of metastatic potential of melanoma and higher invasive capacity (Bittner et al., 2000; Ridley, 2000) . Highly metastatic melanoma tumors, derived from parental tumor cell lines by in vivo passage, show high levels of fibronectin transcript (Clark et al., 2000) . Further, interfering with integrin signaling on melanoma cells by cell-binding fibronectin peptides (RGD-peptides) inhibits experimental metastasis of melanoma cells (Humphries et al., 1986) . These studies suggest that melanoma cells are induced to produce their promigratory matrix, and that interaction of tumor cells with fibronectin contributes to the invasive and metastatic behavior of melanoma cells.
Hepatocyte growth factor/scatter factor (HGF) is a mesenchymally derived cytokine that elicits mitogenic, motogenic and morphogenic activities through activation of its tyrosine kinase receptor encoded by the c-met proto-oncogene. Upon HGF binding, c-Met undergoes autophosphorylation on tyrosine residues that creates docking sites for an array of SH2-containing proteins leading to the activation of several downstream pathways, such as the Ras/MAP Kinase ERK1/2, phosphatidylinositol 3 0 -kinase (PI3K)/Akt, c-Jun-NH 2 -terminal kinase (JNK)/stress-activated protein kinase and focal adhesion kinase pathways. In normal skin, c-Met is present on epithelial cells and melanocytes while HGF is produced mainly by mesenchymal cells and consequently, interacts with its receptor in a paracrine manner (Hsu et al., 2002) . HGF has been shown to stimulate growth and invasiveness in tumor cells and aberrant HGF/c-Met signaling is implicated in a large number of human cancers including melanomas (Trusolino and Comoglio, 2002) . HGF is a mitogen of human melanocytes and overexpression of c-Met correlates with the invasive growth phase of melanoma cells (Natali et al., 1993) . Recent studies by Herlyn's group has shown that most of melanoma cells, but not normal melanocytes, produce HGF, which can induce sustained activation of its receptor (Li et al., 2001) . Hence, an autocrine HGF/c-Met signaling loop may be involved in the development of melanomas. Consistent with this, prolonged HGF stimulation induces the downregulation of the intercellular adhesive molecule E-cadherin that is implicated in the control of melanocyte proliferation (Li et al., 2001) . Finally, transgenic mice broadly expressing HGF develop cutaneous melanoma emphasizing the central role of the HGF/c-Met system in the progression of melanocyte to melanoma (Noonan et al., 2000) .
Little information is available about how fibronectin expression is increased in metastatic melanoma cells. Since fibronectin has a major impact on migration and growth, an understanding of the molecular mechanism by which tumor cells control fibronectin production may provide important information on tumorigenesis and melanoma development. In this study, we show that HGF stimulates fibronectin matrix synthesis by a mechanism dependent on MAP kinase and on induction and activation of the transcription factor Early growth response-1 (Egr-1). Since fibronectin production and HGF/c-Met signaling are correlated with the invasive potential of melanoma, our findings describe a novel mechanism that might contribute to the regulation of melanoma development induced by autocrine HGF signaling or by constitutive activation of MAP kinase pathway.
Results

HGF stimulates fibronectin expression and its matrix assembly in melanoma cells
We hypothesized that HGF modulates the expression of the matrix fibronectin protein in melanoma cells. To test this, we treated MeWo cells with HGF for different times and mRNA fibronectin levels were analysed by real-time RT-PCR analysis. Enhanced fibronectin mRNA was observed at 12 h and reached a maximun at 24 h ( Figure 1a ). This response was suppressed by actinomycin D treatment, indicating that fibronectin activation by HGF requires de novo RNA synthesis (data not shown). The induction of fibronectin mRNA by HGF was also reflected in the protein, which was induced after 24 h of treatment (Figure 1b) . This observation has been extended to the murine B16 melanoma cell line and to a second human melanoma cell line tested 501mel (data not shown). HGF treatment also increased secreted fibronectin protein levels in a time-dependent manner ( Figure 1c) .
Next, we analysed the ability of melanoma cells stimulated by HGF to assemble a fibronectin matrix. Accumulation of fibronectin at the cell surface was analysed by immunofluorescence staining (Figure 1d ). We observed that upregulation of fibronectin protein levels in response to HGF resulted in an accumulation of fibronectin fibrils at the cell surface. These findings indicate that HGF stimulates fibronectin synthesis and matrix assembly in melanoma cells.
HGF-triggered fibronectin expression is mediated by a mechanism dependent on MAP kinase signaling
We then addressed the possible involvement of the MAP kinase/ERK signaling pathway in HGF-induced fibronectin synthesis. We used the U0126, a pharmacological inhibitor of MEK1 and MEK2, the immediate upstream activators of MAP kinases ERK1/2, and analysed HGF-induced fibronectin expression in the presence and absence of U0126. Treatment of MeWo cells with the inhibitor strongly blocked the phosphorylation of MAP kinases ERK1/2 and the expression of fibronectin in response to HGF (Figure 2 ). These results suggest that the MEK/ERK signaling pathway is required for HGF induction of fibronectin in melanoma cells.
HGF induces upregulation of Egr-1 through a Ras/B-RAF/MEK-dependent pathway
Previous studies have shown that the zinc-finger transcription factor Egr-1 regulated fibronectin gene expression in fibrosarcoma and glioblastoma cells (Liu et al., 1996 . These observations prompted us to examine the involvement of Egr-1 in HGF-induced fibronectin expression. We first examined whether Egr-1 mRNA level is regulated by HGF in MeWo cells. Realtime RT-PCR was used to analyse Egr-1 expression. As shown in Figure 3a , MeWo cells exposed to HGF displayed a time-dependent induction of Egr-1 mRNA levels reaching a maximal expression at 30 min and disappearing rapidly afterward. In Western blot analyses of nuclear extracts, HGF was shown to increase Egr-1 protein levels, with maximal levels occurring between 1 and 2 h of stimulation (Figure 3b) . A similar increase in Egr-1 protein and ERK1/2 phosphorylation was also observed in B16 cells. These observations indicate that HGF rapidly and transiently induces Egr-1 mRNA and protein levels in melanoma cells. Interest-ingly, HGF-mediated induction of Egr-1 protein expression was abolished by pretreatment with the MEK inhibitor U0126, but not by the PI3K inhibitor LY294002 or the JNK inhibitor SP600125. Note that only treatment with U0126 inhibited HGF-induced ERK1/2 activation (Figure 3c ). These findings suggest that the MEK/MAP kinase signaling pathway mediates HGF upregulation of Egr-1. To complement the experiment using the pharmacological inhibitor U0126, we determined the effect of dominant-negative mutants of Ras, MEK1, B-Raf and Raf-1 on HGFinduced transcriptional activation of the Egr-1 promoter using a luciferase reporter assay. Cells were transiently transfected with a 1200-bp Egr-1 promoter construct and stimulated or not with HGF for 6 h.
Expression of RasN17 abolished the induction of the Egr-1 promoter promoted by HGF. A similar inhibition was obtained with the dominant-negative mutants of B-Raf (B-RafDN) and MEK1 (MEKDN) (Figure 3d ). These data strongly suggest that the Ras/B-Raf signaling pathway is required for the upregulation of Egr-1 in response to HGF stimulation in melanoma cells. In contrast, expression of the dominant-negative mutant of Raf-1 (Raf-1DN) did not efficiently block the effect of HGF on Egr-1 expression, suggesting that HGF-mediated Egr-1 induction does not require Raf-1 activity ( Figure 3d) . As a control, we found that the Raf-1DN construct blocked serum-induced Egr-1 expression in NIH 3T3 cells (data not shown). (Cohen et al., 1996) . Transient transfection of B16 cells with series of deletion/truncated Egr-1 promoter-reporter luciferase constructs focused our attention on the SRE motifs. Deletion of the region spanning the five SREs dramatically decreased Egr-1 promoter activity. In contrast, deletion of AP-1 and Sp1 sites in the distal portion had no effect on HGF responsiveness. Truncation of regions containing the two proximal SREs or the three distal SREs abolished Egr-1 promoter activity. This result indicates that HGF Figure 2 MAP kinase-dependent induction of fibronectin by HGF in melanoma cells. MeWo cells were serum-starved overnight and where indicated, treated for 30 min with the MEK inhibitor U0126 (10 mM) or with vehicle only (À) prior to stimulation by HGF (50 ng/ml) for the indicated times. Whole-cell extracts were prepared and subjected to Western blot analysis using antifibronectin, anti-phospho-ERK1/2 and anti-ERK2 antibodies. ERK2 was used as a loading control. Data shown are representative of three independent experiments Figure 3 HGF stimulation of Egr-1 expression is mediated by a Ras/B-Raf/MEK-dependent pathway. (a) MeWo cells were serumstarved overnight and then incubated with HGF (50 ng/ml) for the indicated times. Total RNA was isolated and Egr-1 mRNA expression was determined by real-time PCR analysis. mRNA values were expressed as arbitrary units and represent mean 7s.d. of three separate experiments carried out in triplicate. (b) MeWo and B16 cells were serum-starved overnight and incubated with HGF (50 ng/ml) for the indicated times. Nuclear extracts were isolated and Egr-1 expression was analysed by Western blot using anti-Egr-1 antibody. Whole-cell extracts were subjected to Western blot analysis using anti-phospho-ERK1/2 antibodies. The same blot was also probed for TfR to control for loading. (c) Serumstarved MeWo cells were preincubated with 10 mM of MEK inhibitor (U0126), 15 mM of PI3K inhibitor (LY294002) or 20 mM of JNK inhibitor (SP600125) for 30 min and then stimulated with HGF (50 ng/ml) for 1 h. Whole-cell extracts were prepared and subjected to Western blot analysis using anti-Egr-1 and antiphospho-ERK1/2 antibodies. The same blot was also probed for TfR to control for loading. Data shown is representative of three independent experiments. (d) B16 cells were transfected with the full-length Egr-1 promoter luciferase reporter and with empty vector or plasmid encoding dominant-negative form of Ras (RasN17), MEK (MEKDN), B-Raf (B-RafDN) or Raf-1 (Raf-1DN), as indicated. At 24 h after transfection, cells were serumstarved overnight, then stimulated with HGF (50 ng/ml) for 6 h, and harvested for luciferase activity. Luciferase activities were normalized to b-galactosidase activities to eliminate differences in transfection efficiency. Results were expressed as fold induction. Results are the mean 7s.d. of triplicates and are representative of three independent experiments activates the transcription of the Egr-1 gene through a region containing five juxtaposed SREs in the promoter.
Following activation, MAP kinases ERK1/2 translocate into the nucleus to phosphorylate and activate numerous transcription factors, including the ets factor Elk-1. Elk-1 is a component of the ternary complex that binds the SRE and mediates gene transcription in response to growth factors (Buchwalter et al., 2004) . We next performed studies to assess a possible role for Elk-1 in the upregulation of Egr-1 following HGF treatment. HGF stimulated activation of Elk-1 as assessed using a GAL4-Elk-1 reporter expression system. As expected, inhibition of MEK by the U0126 completely reduced the activation of Elk-1 induced by HGF (Figure 4b ). The contribution made by Elk-1 to transcriptional activation of the Egr-1 promoter was confirmed by cotransfection of B16 melanoma cells with the 1200-bp Egr-1 promoter luciferase construct, and a construct encoding a dominant-negative mutant of Elk-1 (Elk-1 383A). In the presence of Elk-1 383A, expression of the luciferase reporter was blocked compared with controls ( Figure 4c ). Thus, it seems likely that activation of Elk-1 by the MEK/MAP kinase signaling pathway regulates SRE-dependent Egr-1 transcription in HGF-stimulated melanoma cells.
HGF-dependent interaction of Egr-1 with the fibronectin promoter
The presence of two functional Egr-1-binding sites within the fibronectin promoter , coupled to the fact that activation of the MAP kinase Figure 4 HGF induced Egr-1 upregulation is dependent on Elk-1 activation. (a) The indicated truncated and deletion mutants of the Egr-1 promoter were assessed for promoter activity in response to HGF. At 24 h after transfection, B16 cells were serum-starved and then stimulated with HGF (50 ng/ml) for 6 h. (b) B16 cells were transfected with plasmids containing Gal4-binding sites upstream of a luciferase reporter and encoding a fusion between Elk-1-and Gal4-DNA-binding domain for Elk-1 transactivation assays. After 24 h, cells were serum-starved, preincubated in the presence or absence of U0126 (10 mM) for 30 min prior incubation with or without HGF for 6 h. (c) The full-length Egr-1 promoter luciferase reporter was cotransfected with either a plasmid directing a dominant-negative form of Elk-1 expression or an empty vector into B16 cells. At 24 h after transfection, cells were serum-starved, then stimulated with HGF (50 ng/ml) for 6 h, and harvested for luciferase activity. Luciferase activities were measured, normalized to b-galactosidase and expressed as fold induction. Results are the mean 7s.d. of triplicates and are representative of three independent experiments HGF stimulates fibronectin expression in melanomas C Gaggioli et al signaling pathway is required for both HGF-induced Egr-1 and fibronectin upregulation, raised the possibility that Egr-1 would contribute to transcriptional activation of the fibronectin gene in response to HGF. Figure 5a displays the nucleotide sequence of the human fibronectin promoter from À105 to þ 14. The predicted Egr-1-binding sites and the TATAA box were delimited. We examined whether Egr-1 binds to this fibronectin promoter region after treatment with HGF. To do this, we performed chromatin immunoprecipitation (ChIP) using Egr-1-specific antibodies. PCR amplification products from reactions with primers flanking the region containing the Egr-1 DNA-binding sites were analysed by 2% agarose gel. The fibronectin promoter was efficiently recovered from immunoprecipitates of Egr-1 prepared from HGF-treated cells, but not from untreated cells or from immunoprecipitates of nonspecific IgG (Figure 5b ). This result indicates that Egr-1 induced by HGF binds to the fibronectin gene promoter in vivo strengthening the potential role of Egr-1 in the regulation of fibronectin expression in response to HGF.
Egr-1 is required for induction of fibronectin matrix production by HGF in melanoma cells
In this set of experiments, we provide evidence that Egr-1 plays an essential role in HGF-induced fibronectin production. We first examined the effect of ectopic expression of Egr-1 on fibronectin production in melanoma cells. We used a constitutively active mutant of Egr-1 (Egr-1*), which is resistant to repression by endogenous transcriptional corepressors (Russo et al., 1993) . MeWo cells were infected with recombinant adenovirus to overexpress Egr-1* (AdEgr-1*) or with adenovirus expressing the green fluorescent protein (GFP) alone as a control. More than 90% of MeWo cells expressed the GFP marker (data not shown). Western blot analyses showed that Egr-1* significantly promoted fibronectin expression in a dose-dependent manner (Figure 6a) . To assess the contribution of the Egr-1 transcription factor to fibronectin expression, MeWo cells were infected with recombinant adenovirus to overexpress NAB2 (AdNAB2). NAB2 is a corepressor molecule that directly binds Egr-1 and inhibits its transactivating potential (Svaren et al., 1996) . As expected, overexpression of NAB2 had no effect on Egr-1 protein induction mediated by HGF (Figure 6b ). To confirm that the expression of NAB2 inhibited Egr-1 function, we monitored Egr-1 activity using an Egr-1-responsive promoter containing four canonical Egrbinding sites. As previously shown, Egr-1-induced activity of the luciferase reporter gene was blocked by coexpression of NAB2 (Figure 6c ). HGF stimulation resulted in a twofold increase in Egr-1-dependent transcriptional activity, indicating that HGF induced a functionally active Egr-1 protein in melanoma cells. Infection of MeWo cells with a control adenovirus (AdGFP) had no effect on HGF-induced Egr-1 activity. In contrast, infection with the adenovirus encoding for NAB2 blocked the stimulation of Egr-1 activity induced by HGF (Figure 6d ). Figure 6e demonstrates that forced expression of NAB2 markedly suppressed fibronectin protein expression induced by HGF, and its accumulation at the extracellular compartment of the cells (data not shown). Collectively, these results support the conclusion that Egr-1 transcriptional activity is required for HGF-induced fibronectin synthesis in melanoma cells.
Expression of fibronectin is correlated with constitutive MAP kinase activity in melanoma cells
The results so far indicated that MAP kinase signaling activates fibronectin expression in response to HGF. Given that enhanced MAP kinase activity ensuing NRas or B-Raf mutation is frequently observed in melanomas (Herlyn and Satyamoorthy, 1996; Brose et al., 2002; Davies et al., 2002) , we wished to determine whether expression of fibronectin is correlated with constitutive MAP kinase signaling pathway. We analysed the expression of fibronectin in normal human melanocytes and in several melanoma cell lines by Western blot analysis. Compared to primary melanocytes, MeWo or 501mel melanoma cells, the highest levels of fibronectin protein were observed in melanoma cell lines known to harbor activating mutation in B-Raf (1205Lu and SK-Mel28) Satyamoorthy et al., 2003) or N-Ras (HMVII) (Figure 7) . Activities of MAP kinases were confirmed by Western blotting using anti phospho-ERK1/2 antibodies. Thus, it is likely that constitutive MAP kinase signaling pathway in 1205Lu, SK-Mel28 and HMVII melanoma cells might contribute to overexpression of fibronectin observed in these cells. 
Discussion
Fibronectin is a cell-substrate adhesion molecule that plays an important role in the migration, invasion and metastasis of several human tumors including melanomas. Although alterations in the expression of fibronectin have been reported to correlate with the acquisition of metastatic properties by melanoma cells, the signal transduction pathways that elicit these changes remain poorly characterized. Here, we demonstrate that HGF-induced MAP kinase/ERK signaling cascade can promote the expression of fibronectin in melanoma cell lines. This regulation occurs at the level of gene transcription and requires the expression and activity of Egr-1. Further, increased fibronectin levels leads to accumulation of surface fibronectin matrix.
Egr-1 was originally identified as an immediate-early gene product that is rapidly induced in response to a variety of extracellular stimuli and environmental stresses (Gashler and Sukhatme, 1995; Thiel and Cibelli, 2002) . Egr-1 is a prototypical member of the Cys 2 -His 2 zinc-finger family of transcription factors that includes 
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Egr-2, Egr-3, NGFI-C and WT1. Once activated, Egr-1 can induce numerous genes implicated in growth, differentiation, wound healing and cancer progression. We show that Egr-1 is upregulated in response to HGF in human and murine melanoma cell lines. This observation is in agreement with a previously reported effect of HGF on Egr-1 induction in a murine melanoma cell line expressing high levels of c-Met and highly responsive to HGF (Recio and Merlino, 2003) .
Previous studies have established an important role for MEK/MAP kinase in mediating Egr-1 expression in response to other growth factors and hormones (Hodge et al., 1998; Tsai et al., 2000; Mechtcheriakova et al., 2001; Wu et al., 2002) . This signaling pathway regulates Egr-1 gene expression mainly through activation of the SREs in the human Egr-1 promoter. Consistent with this, we show that HGF mediates SRE-dependent induction of the Egr-1 gene through the activation of the ternary complex factor Elk-1 via the MEK/MAP kinase pathway. Interestingly, our data demonstrate that expression of Egr-1 is dependent on the activation of the B-Raf signaling pathway. Once activated, Raf family members initiate a signaling cascade that sequentially stimulates MEK1/2 and MAP kinases ERK1/2 (Hagemann and Rapp, 1999) . B-Raf and Raf-1 have overlapping but distinct biological functions (Peyssonnaux and Eychene, 2001) . In melanoma cells, we observed that HGF stimulates the activity of both Raf-1 and B-Raf (C. Gaggioli et al., unpublished data). However, although HGF promotes Raf-1 activity, this activation is not required for HGF-mediated Egr-1 transcriptional induction, suggesting that HGF mediates MEK/ERK activation primarily through activation of B-Raf in melanoma cells. This is consistent with recent studies demonstrating the predominant role of B-Raf in MEK activation in melanocytes and melanoma cells (Hingorani et al., 2003; Wellbrock et al., 2004) .
We provide evidence that Egr-1 participate in the regulation of fibronectin gene expression mediated by HGF. Inhibition of Egr-1 transcriptional activity by forced expression of the corepressor NAB2 abrogates HGF-mediated fibronectin matrix synthesis. The inhibitory effect observed for NAB2 supports an important role of Egr-1 in mediating fibronectin expression in response to HGF. Besides Egr-1, NAB2 can downregulate the activity of Egr-2 and Egr-3, two other members of the Egr family. However, in contrast to Egr-1, Egr-2 and Egr-3 were not induced following cell activation by HGF, suggesting that Egr-1 was the sole target of NAB2 repression in melanoma cells. Although we cannot exclude that NAB2 might interact with and also inhibit other transcription factors, our data support the view that Egr-1 contributes to fibronectin transcription in melanoma cells. This role is in agreement with previous reports showing that Egr-1 increases fibronectin expression in fibrosarcoma and glioblastoma cells (Liu et al., 1996 . Egr-1 also induces fibronectin expression in human endothelial cells (Fu et al., 2003) . Thus, by modulating fibronectin levels in the melanoma cells environment, Egr-1 might play a role in tumor cell adhesion and motility.
The participation of additional transcription factors in HGF-mediated fibronectin expression remains an open question. Although inhibiting MEK/MAP kinase pathway and Egr-1 activity is sufficient to block fibronectin increased by HGF, we cannot exclude the possibility that other factors and/or signaling pathways will participate in modulating the expression of fibronectin. Besides Egr-1, several transcription factors have been shown to regulate fibronectin expression. Transcription of the fibronectin gene can be promoted by activation of nuclear Factor kB, activating protein-1 (AP-1), Wnt/bcatenin, cAMP, JNK and PI3K signaling pathways (Gradl et al., 1999; Hocevar et al., 1999; Lee et al., 2002; Ghosh Choudhury and Abboud, 2004; Guo et al., 2004) . Some of these pathways were activated by HGF in various cell lines. We are currently studying the possible involvement of these pathways in HGFmediated fibronectin expression in melanoma cells.
Constitutive activation of the Ras/MAP kinase signaling pathway is frequently observed in malignant melanomas, as a consequence of activating mutation of the B-Raf and N-Ras genes, or autocrine growth factor stimulation (Herlyn and Satyamoorthy, 1996; Brose et al., 2002; Davies et al., 2002; Satyamoorthy et al., 2003) . Interestingly, we have observed a striking parallel between constitutive activation of the MAP kinase signaling and fibronectin levels in melanoma cell lines that exhibit activating mutations on B-Rraf or NRas. This observation further suggests that MAP kinase-dependent signaling can control fibronectin expression. Based on our findings, it seems likely that in addition to HGF autocrine loop, enhanced activity of the oncogenic Ras-associated MAP kinase pathway might participate in fibronectin overexpression observed in melanomas. (MeWo, SK-Mel28, 1205Lu, 501mel and HMVII) , separated on SDS-PAGE and analysed by Western blotting using antibodies against fibronectin and phospho-ERK1/ 2. Antibody to ERK2 was used as loading control. A single blot representative of three repeats is shown A growing number of reports describe the importance of the HGF/c-Met axis in melanoma progression and metastasis. Thus, the expression of fibronectin in melanoma cells and its relationship to HGF signaling are significant because fibronectin plays an important role in the malignancy of melanoma. Fibronectin has been shown to induce the migration of melanoma cells in vitro (Silletti et al., 1998) and also to control invasiveness of the tumor cells in vivo (Humphries et al., 1986) . Further, fibronectin gene expression is correlated with the metastatic potential of melanoma (Bittner et al., 2000; Clark et al., 2000) . Since HGF signaling is involved in the development of melanoma, our findings support the notion that enhanced fibronectin production may promote melanoma migration and metastasis.
Based on the results of the present study, we propose that HGF may regulate interactions between melanoma cells and the ECM through production of the fibronectin matrix protein. Until recently, little was known about the mechanisms by which HGF regulates tumor/ ECM interactions during the invasive process. It has been shown that HGF increases integrin adhesion and avidity in a mammary adenocarcinoma cell line (Trusolino et al., 2000) . Also, HGF upregulates the expression of osteopontin a matrix protein, which is involved in HGF-induced tumor growth and invasiveness (Medico et al., 2001) . In addition, HGF has been recently implicated in the regulation of the adhesion molecule CD44v6 in melanoma cells (Recio and Merlino, 2003) . Interestingly, CD44v6 upregulation was achieved through induction of Egr-1. Together with this report, our results suggest that Egr-1 might be an important part of the HGF-initiated changes in gene transcription associated with melanoma interaction with ECM during tumor progression and metastasis.
In conclusion, we have demonstrated that HGF induces fibronectin expression in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. The production of fibronectin by melanoma cells in response to HGF may provide a matrix substrate, on which cells can move and become activated. Based on this, our data describe a novel mechanism in which HGF might modulate melanoma cells interaction with the ECM by the induction of fibronectin. This might have important implications for invasion processes, particularly in the context that HGF/c-Met signaling axis is involved in the invasiveness and metastasis of numerous cancers.
Materials and methods
Cell culture
Human primary melanocytes were obtained from foreskins of caucasian children as described (Bertolotto et al., 1998) . Human MeWo, SK-Mel 28, 1205Lu, 501mel, HMVII and murine B16/F10 melanoma cells were cultured under standard conditions (371C in humidified atmosphere containing 5% CO 2 ) and grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 7% fetal bovine serum, 50 mg/ml streptomycin and 100 U/ml penicillin sulfate. Cells were incubated overnight in medium containing 0.2% (w/v) bovine serum albumin (BSA) prior to treatment. Cells were treated with 50 ng/ml HGF where indicated and for the times specified.
Antibodies and reagents
Rabbit anti-fibronectin antibody was purchased from Sigma. Anti-Egr-1, anti-NAB-2 and anti-ERK2 antibodies were from Santa Cruz Biotechnology, Inc. Anti-phospho-ERK1/2 antibodies were from Cell Signaling Technologies. Monoclonal anti-transferrin receptor (TfR) was purchased from Zymed Laboratories Inc. Peroxidase-conjugated secondary antibodies were from Dako Corporation and Texas Red-coupled secondary antibodies were from Molecular Probes. Culture media and primers were from Invitrogen. Chemicals were obtained from Sigma and human recombinant HGF was obtained from R&D systems. Inhibitors U0126 and LY294002 were purchased from Cell Signaling Technology, and SP600125 was from Calbiochem.
Plasmids
The 1.2-kb Egr-1 promoter as well as the deletion constructs cloned in the pXP2 luciferase reporter vector were kindly provided by Dr David Cohen and have been previously described (Cohen et al., 1996) . Mammalian expression vectors encoding B-RafDN, Raf-1DN, MEKDN and RasN17 have been described before (Busca et al., 2000) . pCMV-Egr-1 was generously provided by Drs Dan Mercola and Ve´ronique Baron. pCMV5Elk-1 383A was a kind gift of Dr Peter E Shaw. The Egr-1 responsive reporter plasmid A2ProLuc contains four Egr-binding motifs with a minimal prolactin reporter and has been described elsewhere (Russo et al., 1993; Ehrengruber et al., 2000) . Gal4-Elk-1 and 5XGAL4-luciferase plasmids were from Stratagene.
Transient transfection and luciferase reporter assays
Transfection of B16 cells was performed essentially as described previously using the LipofectAMINE reagent (Invitrogen) (Bertolotto et al., 1998) . Cotransfection with pCMV-b-galactosidase was used as an internal control for transfection efficiency. Cells were harvested 48 h after transfection and assayed for luciferase activity using the Luciferase Assay system (Promega). Results were normalized on the basis of b-galactosidase level in transfected cells. For monitoring Gal4-Elk-1 activation, B16 cells were cotransfected with Gal4DBD-Elk-1 and 5XGAL4-luciferase reporter plasmids and luciferase activities were determined as described above. All experimental values were determined from triplicate wells. Each experiment was repeated at least three times.
Real-time quantitative PCR
Total RNA from cells was isolated at the indicated times using the TRIzol reagent following the instructions from the manufacturer (Invitrogen). After treatment with Dnase I, 1 mg of total RNA was reverse transcribed using random priming and Superscript II reverse transcriptase (Invitrogen). Real-time PCR was performed in an ABI PRISM 5700 Sequence Detector System (Applied Biosystems) using the SYBR Green detection protocol as outlined by the manufacturer. Gene-specific primers were designed using the Primer Express software (Applied Biosystems). Relative expression level of target genes was normalized for RNA concentrations with two different house-keeping genes (GAPDH and bactin). mRNA values are expressed as arbitrary units and represent mean 7s.d. of triplicates and are representative of two independent experiments.
Extracellular fibronectin detection by immunofluorescence staining
Fibronectin matrix was analysed by immunofluorescence staining of cell monolayers. Cells were fixed with 3% paraformaldehyde in PBS for 20 min, and incubated for 1 h with the polyclonal rabbit anti-fibronectin antibodies diluted in PBS containing 1% BSA. Texas Red-coupled secondary antibodies were used for detection. Cells were observed using a Zeiss axiophot epifluorescence microscope, and representative fields were shown.
ChIP assay
The ChIP assay was performed using the ChIP assay kit (Upstate Biotechnology) following the instructions provided by the manufacturer. Rabbit anti-Egr-1 (sc-189) or rabbit IgG were used to immunoprecipitate DNA-containing complexes. PCR was performed with primers complementary to the fibronectin promoter region containing the previously described Egr-1 binding sites . The primer sequences are as follows: sense primer: 5 0 -GCCAATCG GCGCGCGGTCGGC-3 0 ; antisense primer: 5 0 -CCCGCTCG CGCCTGGGGTTC-3 0 . DNA samples were analysed by 2% agarose gel with ethidium bromide.
Adenovirus infection
The generation of recombinant adenoviruses expressing constitutively active Egr-1 (AdEgr-1*), NAB2 (AdNAB2) and the control adenovirus AdGFP was described previously (Ehrengruber et al., 2000) . Egr-1* was not responsive to NAB repression due to a point mutation (I293F) in its NAB-binding domain (Russo et al., 1993) . MeWo cells were cultured in sixwell plates and infected at 70% confluence with AdGFP, AdEGR-1* or AdNAB2 adenoviruses. The appropriate titer for viruses was determined by the addition of various dilutions of each adenovirus to HEK293 cells cultured in six-well plates to 70% confluence. Cells were analysed 48 h postinfection. Almost 100% infection efficiency was obtained with an MOI of 6 (data not shown).
Protein analysis
After HGF treatment, cells in six-well plates were solubilized on ice in RIPA buffer containing 50 mM Tris pH 7.6, 150 mM NaCl, 5 mM NaF, 2.5 mM Na 4 P 2 O 7 , 1 mM Na 3 VO 4 , 0.1% SDS, 0.5 % sodium deoxycholate, and a Protease Inhibitor Cocktail (Roche Applied Science) supplemented with 1% NP-40. Lysates were then cleared and adjusted to equal protein amounts. For the detection of Egr-1, crude nuclear extracts were prepared at the indicated times as described (Chavey et al., 2003) . In total, 30 mg of protein lysates were separated by SDS-PAGE and analysed by Western Blotting. Proteins were transferred to polyvinylidene difluoride membranes (Millipore) and probed with primary antibodies. Signals were visualized with secondary antibodies coupled to peroxidase, using enhanced chemiluminescence (ECL) system (Amersham Pharmacia Biotech).
